Share
In partnership with Raymond James and Farragut Square Group, Grant Thornton Stax recently hosted a breakfast event to discuss emerging opportunities in pharma technology and tech-enabled services across the clinical development lifecycle. Joining us for the morning were several leading Private Equity firms and Investment Banks.
The agenda covered a comprehensive view of how technology is transforming the pharmaceutical industry and where investors are focusing their attention, as well as a look into the evolution of the pharma tech stack across the drug development lifecycle. A key focal point was investor sentiment and valuation trends from recent transactions that are informing forward-looking investment considerations, including assets expected to come to market in 2026 and 2027.
Focusing more on 2026, our Healthcare team shared some high-potential investment themes stemming from AI-driven scientific enablement and automation. Most importantly, the discussion centered around the growing role of artificial intelligence in preclinical drug discovery, along with the importance of leveraging structured data systems like ELNs and LIMS in order to unlock AI’s full value.
The event covered a sector characterized by digital transformation, AI integration, and fragmented ecosystems that offer significant opportunities for consolidation and innovation. Some other key themes covered during the event include:
- Pharma Tech Evolution Across Drug Development
- Commercialization Trends
- M&A Landscape
To learn more about the event, Pharma Tech, or our Healthcare vertical, click the button below to contact us directly.
Read More
The Mispricing of ESG: A Capital Markets POV on Sustainability, Value Creation, and Competitive Edge
